Literature DB >> 6809468

Elimination of infused amino acids from plasma of control subjects and of patients with cirrhosis of the liver.

H Vilstrup, D Bucher, B Krog, S E Damgård.   

Abstract

In four control subjects and four patients with cirrhosis of the liver a multiple amino acid mixture was infused for 12 h at a constant rate of 68 and 56 mumol alpha-amino N/s, respectively. Before infusion the plasma amino N concentration was 2.4 +/- 0.2 (mean +/- SD) mmol/l in control subjects and 3.5 +/- 0.7 mmol/in patients (P less than 0.025). The concentration of alanine, proline, arginine, tyrosine, and citrulline was significantly increased in the cirrhosis group. 12 h after the infusion began approximately constant amino N concentrations of 11.4 +/- 1.8 mmol/l in controls and 13.7 +/- 3.9 mmol/l in patients were attained, and the urea N synthesis rate was 63 +/- 17 and 44 +/- 8 mumol/s, respectively (P less than 0.05). After correction for loss of amino acids in urine this means that on the average 94 per cent of the N load was recovered as urea. The plasma clearance of infused amino acids, calculated as the ratio between infusion rate and steady state concentration, was 6.0 +/- 1.2 and 4.1 +/- 0.9 ml/s for amino N in the control and cirrhosis group, respectively (P less than 0.025). The clearance of individual amino acids ranged between 2.5 and 28 ml/s. The clearance of most amino acids was decreased in the cirrhosis groups, and of glycine, proline, lysine, threonine, and arginine significantly so (P less than 0.05), reflecting accumulation of amino acids in patients. This indicates that a primary defect in the conversion of amino N in cirrhosis is the reduced urea synthesis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6809468     DOI: 10.1111/j.1365-2362.1982.tb00993.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

1.  Metabolic effects of liver transplantation in cirrhotic patients.

Authors:  L Luzi; G Perseghin; E Regalia; L P Sereni; A Battezzati; D Baratti; E Bianchi; I Terruzzi; H Hilden; L C Groop; A Pulvirenti; M R Taskinen; L Gennari; V Mazzaferro
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 2.  Mechanisms and consequences of the impaired trans-sulphuration pathway in liver disease: Part II. Clinical consequences and potential for pharmacological intervention in cirrhosis.

Authors:  E Pisi; G Marchesini
Journal:  Drugs       Date:  1990       Impact factor: 9.546

3.  [Tryptophan metabolism in liver diseases: a pharmacokinetic and enzymatic study].

Authors:  M Rössle; R Herz; B Klein; W Gerok
Journal:  Klin Wochenschr       Date:  1986-07-01

4.  The disposition of intravenous L-tryptophan in healthy subjects and in patients with liver disease.

Authors:  M Rössle; R Herz; K D Mullen; D B Jones
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

5.  Association of eNOS Gene Polymorphisms G894T and T-786C with Risk of Hepatorenal Syndrome.

Authors:  Yuksel Seckin; Ali Yigit; Elif Yesilada; Gonca Gulbay; Yasir Furkan Cagin; Harika Gozukara; Yılmaz Bılgıc; Oguzhan Yildirim; Yusuf Turkoz; Zeynep Aksungur
Journal:  Gastroenterol Res Pract       Date:  2016-08-10       Impact factor: 2.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.